You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Advances in Cancer Research
Is it advisable to go back from bedside to the bench? During the last decade, few topics encountered such a broad interest in bio- gy and medicine as angiogenesis. The amazing ability of the body to restore blood flow by induction of blood vessel growth as part of an adaptive process has alarmed physicians dealing with diseases in which angiogenesis is either exaggerated (as in tumors) or too slow (as in ischemic diseases of heart and brain). Not surprisingly, pro- and antiangiogenic strategies have found their way into clinical trials. For instance, for the USA, the NIH website in early 2004 displayed 38 clinical studies involving either pro- or antiangiogenic th- apies. Given the expected ...
Metastasis is responsible for a large burden of morbidity and mortality among cancer patients, and currently few therapies specifically target metastatic disease. Further scientific dissection of the underlying pathways is required to pave the way for new therapeutic targets. This groundbreaking new text comprehensively covers the processes underlying cancer metastasis and the clinical treatment of metastatic disease. Whereas previous volumes have been compendia of laboratory research articles, the internationally renowned authors of this volume have summarized the state-of-the-art research in the metastasis field. A major section covers the cellular and molecular pathways of metastasis and experimental techniques and the systems and models applied in this field. Subsequently, the clinical aspects of the major cancer types are considered, focusing on disease-specific research and therapeutic approaches to metastatic disease. The focus is on novel pathophysiological insights and emerging therapies; future directions for research and unmet clinical needs are also discussed.
The National Clinical Trials Network (NCTN) supported by the National Cancer Institute (NCI) has played an integral role in cancer research and in establishing the standard of care for cancer patients for more than 50 years. Formerly known as the NCI Clinical Trials Cooperative Group Program, the NCTN is comprised of more than 2,100 institutions and 14,000 investigators, who enroll more than 20,000 cancer patients in clinical trials each year across the United States and internationally. Recognizing the recent transformative advances in cancer research that necessitate modernization in how cancer clinical trials are run, as well as inefficiencies and other challenges impeding the national ca...
Completely revised and updated, and now in full color throughout, the Fourth Edition of this definitive reference is a must for all clinicians who treat breast diseases. Leading experts summarize the current knowledge of breast diseases, including their clinical features, management, underlying biologies, and epidemiologies. In addition to complete coverage of malignant breast diseases, benign diseases are discussed in relation to subsequent breast cancer development. The book reviews all major clinical trials and summarizes the information they provide on early detection and management of breast cancer. Close attention is also given to the increasing importance of molecular biology and gene...
The fifth edition of the only comprehensive text dealing exclusively with rare or infrequently encountered malignancies in adults and children is an essential resource for any clinical oncologist. Encompasses all the information needed to diagnose and manage uncommon cancers, an area where advice and guidance is typically scarce Fully revised with new material and an evidence-based, teach-by-example approach Provides insight on real-world decision making in the clinical setting Edited and authored by a highly experienced and senior team of medical oncologists, radiation oncologists, and other specialists, giving a balanced and complete overview Extensively illustrated in full color throughout, including heat maps to show gene expression
Precision medicine is an emerging practice by which clinicians aim to deliver a personalized treatment program to affected patients based on information gained from their individual clinical and biological profiles. In the context of precise cancer immunotherapy, multi-omics, high-throughput sequencing, big data, and other approaches serve to screen new predictive factors for immunotherapy response and prognosis in cancer patients.
This issue of the Surgical Oncology Clinics will focus on new advances in Breast Cancer Surgery, and will include articles on Chemoprevention, Breast MRI, Genomics, Sentinel Node Biopsy, Extra-axillary Sentinel Nodes, Skin-Sparing and Nipple Sparing Mastectomy, Oncoplastic Techniques, Neoadjuvant Hormonal Therapy, Neoadjuvant Chemotherapy, Adjuvant Hormonal Therapy, Adjuvant Chemotherapy, and Biologic Targeted Therapies.